- €86.19bn
- €103.69bn
- €46.72bn
US FDA approves Orca Bio's blood cancer therapy
US FDA declines to approve Unicycive's kidney disease drug (updated)
Brief: Sanofi’S Nexviazyme Met All Primary And Secondary Endpoints In Infantile-Onset Pompe Disease Phase 3 Study
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Europe must rethink medicine pricing or risk losing investments, pharma lobby chief says (updated)
Europe must rethink medicine pricing or risk losing investments, pharma lobby chief says
Brief: Sanofi's Wayrilz Approved In Japan For Immune Thrombocytopenia
Brief: Sanofi's Cenrifki Approved In The EU For Secondary Progressive Multiple Sclerosis Without Relapses
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
Brief: Sanofi Appoints Paulo Fontoura As Global Head Of RD Pharma
Brief: Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
Moderna's mRNA flu vaccine backed by FDA advisers (updated)
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
Factbox: Global drugmakers invest billions to boost US presence
Europe Research Roundup: Banca Generali, Ferrari, Prysmian